Understanding and managing parkinsonism in patients with glucocerebrosidase mutations

Bibliography

• ONeudorfer, NGiladi, DElstein, et al. Occurrence of Parkinson’s syndrome in type I Gaucher disease. QJM 1996;89(9):691-4
   PubMed Web of Science ®Google Scholar
• NTayebi, JWalker, BStubblefield, et al. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 2003;79(2):104-9
   PubMed Web of Science ®Google Scholar
• BBembi, SZambito Marsala, ESidransky, et al. Gaucher’s disease with Parkinson’s disease: clinical and pathological aspects. Neurology 2003;61(1):99-101
   PubMed Web of Science ®Google Scholar
• ALwin, EOrvisky, OGoker-Alpan, et al. Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004;81(1):70-3
   PubMed Web of Science ®Google Scholar
• OGoker-Alpan, RSchiffmann, MELaMarca, et al. Parkinsonism among Gaucher disease carriers. J Med Genet 2004;41(12):937-40
   PubMed Web of Science ®Google Scholar
• ESidransky. Heterozygosity for a Mendelian disorder as a risk factor for complex disease. Clin Genet 2006;70(4):275-82
   Google Scholar
• NSetó-Salvia, JPagonabarraga, HHoulden, et al. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson’s disease course. Mov Disord 2012;27(3):393-9
   PubMed Web of Science ®Google Scholar
• QYSun, JFGuo, LWang, et al. Glucocerebrosidase gene L444P mutation is a risk factor for Parkinson’s disease in Chinese population. Mov Disord 2010;25(8):1005-11
   Google Scholar
• ANoreau, JBRivière, SDiab, et al. Glucocerebrosidase mutations in a French-Canadian Parkinson’s disease cohort. Can J Neurol Sci 2011;38(5):772-3
   Google Scholar
• SLesage, CCondroyer, NHecham, et al. Mutations in the glucocerebrosidase gene confer a risk for Parkinson disease in North Africa. Neurology 2011;76(3):301-3
   Google Scholar
• FYHu, JXi, JGuo, et al. Association of the glucocerebrosidase N370S allele with Parkinson’s disease in two separate Chinese Han populations of mainland China. Eur J Neurol 2010;17(12):1476-8
   Google Scholar
• ESidransky, MANalls, JOAasly, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 2009;361(17):1651-61
   PubMed Web of Science ®Google Scholar
• MANalls, RDuran, GLopez, et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 2013;70(6):727-35
   PubMed Web of Science ®Google Scholar
• MSiebert, ESidransky, WWestbroek. Glucocerebrosidase is shaking up the synucleinopathies. Brain 2014;137(Pt 5):1304-22
   PubMed Web of Science ®Google Scholar
• SLesage, ABrice. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009;18(R1):R48-59
   PubMed Web of Science ®Google Scholar
• JNeumann, JBras, EDeas, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 2009;132(Pt 7):1783-94
   PubMed Web of Science ®Google Scholar
• AJHughes, SEDaniel, LKilford, AJLees. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55(3):181-4
   PubMed Web of Science ®Google Scholar
• HBraak, KDel Tredici, URüb, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24(2):197-211
   PubMed Web of Science ®Google Scholar
• TPringsheim, NJette, AFrolkis, TDSteeves. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2014;29(13):1583-90
   PubMed Web of Science ®Google Scholar
• BERosenbloom, NJWeinreb. Gaucher disease: a comprehensive review. Crit Rev Oncog 2013;18(3):163-75
   PubMedGoogle Scholar
• NJWeinreb, HCAndersson, MBanikazemi, et al. Prevalence of type 1 Gaucher disease in the United States. Arch Intern Med 2008;168(3):326-7; author reply 327-8
   Google Scholar
• OGoker-Alpan, GLopez, JVithayathil, et al. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 2008;65(10):1353-7
   PubMedGoogle Scholar
• IGMcKeith. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006;9(3 Suppl):417-23
   PubMedGoogle Scholar
• BRosenbloom, MBalwani, JMBronstein, et al. The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells Mol Dis 2011;46(1):95-102
   PubMed Web of Science ®Google Scholar
• MRaja, AAzzoni, FGiona, et al. Movement and mood disorder in two brothers with Gaucher disease. Clin Genet 2007;72(4):357-61
   Google Scholar
• KWong, ESidransky, AVerma, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 2004;82(3):192-207
   PubMed Web of Science ®Google Scholar
• EBChetrit, RNAlcalay, BSteiner-Birmanns, et al. Phenotype in patients with Gaucher disease and Parkinson disease. Blood Cells Mol Dis 2013;50(3):218-21
   Google Scholar
• AJLees, JHardy, TRevesz. Parkinson’s disease. Lancet 2009;373(9680):2055-66
   PubMed Web of Science ®Google Scholar
• CLHuang, YHWu-Chou, SCLai, et al. Contribution of glucocerebrosidase mutation in a large cohort of sporadic Parkinson’s disease in Taiwan. Eur J Neurol 2011;18(10):1227-32
   Google Scholar
• YRWu, CMChen, CYChao, et al. Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol Neurosurg Psychiatry 2007;78(9):977-9
   Google Scholar
• KKalinderi, SBostantjopoulou, CPaisan-Ruiz, et al. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci Lett 2009;452(2):87-9
   Google Scholar
• MMoraitou, GHadjigeorgiou, IMonopolis, et al. beta-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson’s disease. Mol Genet Metab 2011;104(1-2):149-52
   Google Scholar
• LNClark, BMRoss, YWang, et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 2007;69(12):1270-7
   PubMed Web of Science ®Google Scholar
• JGBecker, GMPastores, ADi Rocco, et al. Parkinson’s disease in patients and obligate carriers of Gaucher disease. Parkinsonism Relat Disord 2013;19(1):129-31
   Google Scholar
• LMChahine, JQiang, EAshbridge, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol 2013;70(7):852-8
   PubMed Web of Science ®Google Scholar
• WCNichols, NPankratz, DKMarek, et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 2009;72(4):310-16
   PubMed Web of Science ®Google Scholar
• ZGan-Or, NGiladi, URozovski, et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008;70(24):2277-83
   PubMed Web of Science ®Google Scholar
• EBeutler, TGelbart, CRScott. Hematologically important mutations: gaucher disease. Blood Cells Mol Dis 2005;35(3):355-64
   PubMed Web of Science ®Google Scholar
• CPont-Sunyer, AHotter, CGaig, et al. The onset of nonmotor symptoms in Parkinson’s disease (The ONSET PD study). Mov Disord 2015;30(2):229-37
   PubMed Web of Science ®Google Scholar
• JGGoldman, RPostuma. Premotor and nonmotor features of Parkinson’s disease. Curr Opin Neurol 2014;27(4):434-41
   PubMed Web of Science ®Google Scholar
• PBarone, AAntonini, CColosimo, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 2009;24(11):1641-9
   PubMed Web of Science ®Google Scholar
• GWDuncan, TKKhoo, AJYarnall, et al. Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms. Mov Disord 2014;29(2):195-202
   PubMed Web of Science ®Google Scholar
• TBöttcher, ARolfs, BMeyer, et al. Clinical, genetic, and brain sonographic features related to Parkinson’s disease in Gaucher disease. J Neurol 2013;260(10):2523-31
   Google Scholar
• RSaunders-Pullman, JHagenah, VDhawan, et al. Gaucher disease ascertained through a Parkinson’s center: imaging and clinical characterization. Mov Disord 2010;25(10):1364-72
   Google Scholar
• RNAlcalay, ECaccappolo, HMejia-Santana, et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012;78(18):1434-40
   PubMed Web of Science ®Google Scholar
• KBrockmann, KSrulijes, AKHauser, et al. GBA-associated PD presents with nonmotor characteristics. Neurology 2011;77(3):276-80
   PubMed Web of Science ®Google Scholar
• AMcNeill, RDuran, CProukakis, et al. Hyposmia and cognitive impairment in Gaucher disease patients and carriers. Mov Disord 2012;27(4):526-32
   PubMed Web of Science ®Google Scholar
• OGoker-Alpan, JCMasdeu, PDKohn, et al. The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain 2012;135(Pt 8):2440-8
   PubMedGoogle Scholar
• MBeavan, AMcNeill, CProukakis, et al. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol 2014;72(2):201-8
   Google Scholar
• COssig, HReichmann. Treatment Strategies in early and advanced Parkinson disease. Neurol Clin 2015;33(1):19-37
   Google Scholar
• CCAquino, SHFox. Clinical spectrum of levodopa-induced complications. Mov Disord 2015;30(1):80-9
   PubMed Web of Science ®Google Scholar
• ORascol, CJFitzer-Attas, RHauser, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011;10(5):415-23
   PubMed Web of Science ®Google Scholar
• PLMcCormack. Rasagiline: a review of its use in the treatment of idiopathic Parkinson’s disease. CNS Drugs 2014;28(11):1083-97
   PubMed Web of Science ®Google Scholar
• JPFinberg, KGillman. Selective inhibitors of monoamine oxidase type B and the “cheese effect”. Int Rev Neurobiol 2011;100:169-90
   PubMed Web of Science ®Google Scholar
• MPanisset, JJChen, SHRhyee, et al. Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacotherapy 2014;34(12):1250-8
   PubMed Web of Science ®Google Scholar
• MAndrejak, CTribouilloy. Drug-induced valvular heart disease: an update. Arch Cardiovasc Dis 2013;106(5):333-9
   Google Scholar
• MPilleri, AAntonini. Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease. Expert Opin Drug Saf 2015;14(2):281-94
   PubMed Web of Science ®Google Scholar
• PJGarcia-Ruiz, JCMartinez Castrillo, AAlonso-Canovas, et al. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry 2014;85(8):840-4
   PubMed Web of Science ®Google Scholar
• RPahwa, KELyons. Treatment of early Parkinson’s disease. Curr Opin Neurol 2014;27(4):442-9
   Google Scholar
• PGFrisina, HRTenenbaum, JCBorod, NSFoldi. The effects of antidepressants in Parkinson’s disease: a meta-analysis. Int J Neurosci 2008;118(5):667-82
   Web of Science ®Google Scholar
• MCMayo, YBordelon. Dementia with Lewy bodies. Semin Neurol 2014;34(2):182-8
   PubMed Web of Science ®Google Scholar
• NWBarton, ROBrady, JMDambrosia, et al. Replacement therapy for inherited enzyme deficiency – macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 1991;324(21):1464-70
   PubMed Web of Science ®Google Scholar
• AZimran, DElstein, ELevy-Lahad, et al. Replacement therapy with imiglucerase for type 1 Gaucher’s disease. Lancet 1995;345(8963):1479-80
   Google Scholar
• GMPastores, BRosenbloom, NWeinreb, et al. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability. Genet Med 2014;16(5):359-66
   PubMed Web of Science ®Google Scholar
• GAGrabowski, MGolembo, YShaaltiel. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology. Mol Genet Metab 2014;112(1):1-8
   PubMed Web of Science ®Google Scholar
• AZimran, EBrill-Almon, RChertkoff, et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011;118(22):5767-73
   PubMed Web of Science ®Google Scholar
• WLSimpson, GHermann, MBalwani. Imaging of Gaucher disease. World J Radiol 2014;6(9):657-68
   Google Scholar
• Lvan Dussen, MBiegstraaten, MGDijkgraaf, CEHollak. Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications. Orphanet J Rare Dis 2014;9:112
   PubMed Web of Science ®Google Scholar
• NCLee, YHChien, SLWong, et al. Outcome of early-treated type III Gaucher disease patients. Blood Cells Mol Dis 2014;53(3):105-9
   PubMed Web of Science ®Google Scholar
• RSchiffmann, EJFitzgibbon, CHarris, et al. Randomized, controlled trial of miglustat in Gaucher’s disease type 3. Ann Neurol 2008;64(5):514-22
   PubMed Web of Science ®Google Scholar
• EBVitner, AVardi, TMCox, AHFuterman. Emerging therapeutic targets for Gaucher disease. Expert Opin Ther Targets 2015;19(3):321-34
   PubMed Web of Science ®Google Scholar
• RMPoole. Eliglustat: first global approval. Drugs 2014;74(15):1829-36
   Google Scholar
• RSKamath, ELukina, NWatman, et al. Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiol 2014;43(10):1353-60
   PubMed Web of Science ®Google Scholar
• ELukina, NWatman, MDragosky, et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis 2014;53(4):274-6
   PubMed Web of Science ®Google Scholar
• NJWeinreb, MDCappellini, TMCox, et al. A validated disease severity scoring system for adults with type 1 Gaucher disease. Genet Med 2010;12(1):44-51
   PubMed Web of Science ®Google Scholar
• ORingdén, CGGroth, AErikson, et al. Ten years’ experience of bone marrow transplantation for Gaucher disease. Transplantation 1995;59(6):864-70
   PubMed Web of Science ®Google Scholar
• SIto, AJBarrett. Gauchers disease – a reappraisal of hematopoietic stem cell transplantation. Pediatr Hematol Oncol 2013;30(2):61-70
   PubMed Web of Science ®Google Scholar
• JABarranger, EORice, JDunigan, et al. Gaucher’s disease: studies of gene transfer to haematopoietic cells. Baillieres Clin Haematol 1997;10(4):765-78
   Google Scholar
• IBEnquist, ENilsson, JEMånsson, et al. Successful low-risk hematopoietic cell therapy in a mouse model of type 1 Gaucher disease. Stem Cells 2009;27(3):744-52
   Google Scholar
• SPSardi, JClarke, CViel, et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci USA 2013;110(9):3537-42
   PubMed Web of Science ®Google Scholar
• GHMaegawa, MBTropak, JDButtner, et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem 2009;284(35):23502-16
   PubMed Web of Science ®Google Scholar
• AZimran, GAltarescu, DElstein. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol Dis 2013;50(2):134-7
   PubMed Web of Science ®Google Scholar
• KEMurphy, AMGysbers, SKAbbott, et al. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson’s disease. Brain 2014;137(Pt 3):834-48
   PubMed Web of Science ®Google Scholar
• ATrapero, ALlebaria. Glucocerebrosidase inhibitors: future drugs for the treatment of Gaucher disease? Future Med Chem 2014;6(9):975-8
   Google Scholar
• EGoldin, WZheng, OMotabar, et al. High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase. PLoS One 2012;7(1):e29861
   PubMed Web of Science ®Google Scholar
• SFahn. The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord 2015;30(1):4-18
   PubMed Web of Science ®Google Scholar
• RAHauser, DSilver, AChoudhry, et al. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson’s disease. Mov Disord 2014;29(8):1028-34
   PubMed Web of Science ®Google Scholar
• VGRasmussen, KØstergaard, EDupont, SHPoulsen. The risk of valvular regurgitation in patients with Parkinson’s disease treated with dopamine receptor agonists. Mov Disord 2011;26(5):801-6
   PubMed Web of Science ®Google Scholar
• AHSchapira, PBarone, RAHauser, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology 2011;77(8):767-74
   PubMed Web of Science ®Google Scholar
• FStocchi, LGiorgi, BHunter, AHSchapira. PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease. Mov Disord 2011;26(7):1259-65
   PubMed Web of Science ®Google Scholar
• RPahwa, CMTanner, RAHauser, et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson’s disease (EASED Study). Mov Disord 2015. [Epub ahead of print]
   Google Scholar
• RKatzenschlager, CSampaio, JCosta, ALees. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev 2003(2):CD003735
   Google Scholar
• EMoro, AMLozano, PPollak, et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson’s disease. Mov Disord 2010;25(5):578-86
   PubMed Web of Science ®Google Scholar
• AFunkiewiez, CArdouin, ECaputo, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004;75(6):834-9
   PubMed Web of Science ®Google Scholar
• SWight, NMiller. Lee Silverman Voice Treatment for people with Parkinson’s: audit of outcomes in a routine clinic. Int J Lang Commun Disord 2015;50(2):215-25
   Google Scholar
• LTickle-Degnen, TEllis, MHSaint-Hilaire, et al. Self-management rehabilitation and health-related quality of life in Parkinson’s disease: a randomized controlled trial. Mov Disord 2010;25(2):194-204
   PubMed Web of Science ®Google Scholar
• NEAllen, CGCanning, CSherrington, et al. The effects of an exercise program on fall risk factors in people with Parkinson’s disease: a randomized controlled trial. Mov Disord 2010;25(9):1217-25
   PubMed Web of Science ®Google Scholar
• RDDobkin, MMenza, KLBienfait. CBT for the treatment of depression in Parkinson’s disease: a promising nonpharmacological approach. Expert Rev Neurother 2008;8(1):27-35
   PubMedGoogle Scholar
• VAGoodwin, SHRichards, RSTaylor, et al. The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2008;23(5):631-40
   PubMed Web of Science ®Google Scholar
• GPagano, GRengo, GPasqualetti, et al. Cholinesterase inhibitors for Parkinson’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2014. [ Epub ahead of print]
   Google Scholar
• MRolinski, CFox, IMaidment, RMcShane. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev 2012;3:CD006504
   PubMed Web of Science ®Google Scholar
• MHasnain. Psychosis in Parkinson’s disease: therapeutic options. Drugs Today (Barc) 2011;47(5):353-67
   Google Scholar
• JHFriedman. Atypical antipsychotic drugs in the treatment of Parkinson’s disease. J Pharm Pract 2011;24(6):534-40
   PubMedGoogle Scholar
• MRLemke. Depressive symptoms in Parkinson’s disease. Eur J Neurol 2008;15(Suppl 1):21-5
   Google Scholar
• PBarone. Treatment of depressive symptoms in Parkinson’s disease. Eur J Neurol 2011;18(Suppl 1):11-15
   Google Scholar
• DWeintraub, KHMorales, PJMoberg, et al. Antidepressant studies in Parkinson’s disease: a review and meta-analysis. Mov Disord 2005;20(9):1161-9
   PubMed Web of Science ®Google Scholar
• DAGallagher, ASchrag. Psychosis, apathy, depression and anxiety in Parkinson’s disease. Neurobiol Dis 2012;46(3):581-9
   PubMed Web of Science ®Google Scholar
• RDPrediger, FCMatheus, MLSchwarzbold, et al. Anxiety in Parkinson’s disease: a critical review of experimental and clinical studies. Neuropharmacology 2012;62(1):115-24
   PubMed Web of Science ®Google Scholar
• FFerreri, CAgbokou, SGauthier. Recognition and management of neuropsychiatric complications in Parkinson’s disease. CMAJ 2006;175(12):1545-52
   Google Scholar
• LMTrotti, DLBliwise. Treatment of the sleep disorders associated with Parkinson’s disease. Neurotherapeutics 2014;11(1):68-77
   PubMed Web of Science ®Google Scholar
• RNAurora, RSZak, RKMaganti, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 2010;6(1):85-95
   PubMed Web of Science ®Google Scholar
• RNAurora, DAKristo, SRBista, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults – an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep 2012;35(8):1039-62
   PubMed Web of Science ®Google Scholar
• DGarcia-Borreguero, LFerini-Strambi, RKohnen, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol 2012;19(11):1385-96
   Web of Science ®Google Scholar
• IVLitvinenko, IVKrasakov, OVTikhomirova. [Sleep disorders in Parkinson’s disease without dementia: a comparative randomized controlled study of melatonin and clonazepam]. Zh Nevrol Psikhiatr Im S S Korsakova 2012;112(12):26-30
   Google Scholar
• YDauvilliers. Insomnia in patients with neurodegenerative conditions. Sleep Med 2007;8(Suppl 4):S27-34
   Google Scholar
• GMayer, PJennum, DRiemann, YDauvilliers. Insomnia in central neurologic diseases – occurrence and management. Sleep Med Rev 2011;15(6):369-78
   Google Scholar
• MMenza, RDDobkin, HMarin, et al. Treatment of insomnia in Parkinson’s disease: a controlled trial of eszopiclone and placebo. Mov Disord 2010;25(11):1708-14
   PubMed Web of Science ®Google Scholar
• VSrinivasan, DPCardinali, USSrinivasan, et al. Therapeutic potential of melatonin and its analogs in Parkinson’s disease: focus on sleep and neuroprotection. Ther Adv Neurol Disord 2011;4(5):297-317
   Google Scholar
• MSophie, BFord. Management of pain in Parkinson’s disease. CNS Drugs 2012;26(11):937-48
   Google Scholar
• ADHa, JJankovic. Pain in Parkinson’s disease. Mov Disord 2012;27(4):485-91
   PubMed Web of Science ®Google Scholar
• AQRana, AKabir, MJesudasan, et al. Pain in Parkinson’s disease: analysis and literature review. Clin Neurol Neurosurg 2013;115(11):2313-17
   PubMed Web of Science ®Google Scholar
• VCWallace, KRChaudhuri. Unexplained lower limb pain in Parkinson’s disease: a phenotypic variant of “painful Parkinson’s disease”. Parkinsonism Relat Disord 2014;20(1):122-4
   Google Scholar
• JJankovic. Disease-oriented approach to botulinum toxin use. Toxicon 2009;54(5):614-23
   PubMed Web of Science ®Google Scholar
• JHFriedman, AAbrantes, LHSweet. Fatigue in Parkinson’s disease. Expert Opin Pharmacother 2011;12(13):1999-2007
   PubMed Web of Science ®Google Scholar
• HLTyne, JTaylor, GABaker, MJSteiger. Modafinil for Parkinson’s disease fatigue. J Neurol 2010;257(3):452-6
   Web of Science ®Google Scholar
• JSLou, DMDimitrova, BSPark, et al. Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study. Clin Neuropharmacol 2009;32(6):305-10
   PubMed Web of Science ®Google Scholar
• DAMendonça, KMenezes, MSJog. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 2007;22(14):2070-6
   PubMed Web of Science ®Google Scholar
• JGNutt, JHCarter, NECarlson. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. Arch Neurol 2007;64(3):319-23
   PubMedGoogle Scholar